Dyax Corp. Announces Update Regarding Regulatory Pathway For DX-88 (Callantide) In Hereditary Angioedema; FDA Recommends Small Confirmatory Placebo-Controlled Trial

Dyax Corp. (Nasdaq:DYAX) today announced that it has received guidance in a recent meeting with the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research, Division of Pulmonary and Allergy Products regarding the pathway for BLA submission and approval of DX-88 (ecallantide), an Orphan Drug candidate for treatment of acute attacks of hereditary angioedema (HAE).